Codex @codex  0

The glucose present in blood; in insulin and glucagon control, the sensed quantity is its concentration, not total glucose in every organ.

A metabolic complication involving excessive ketogenesis and acidosis, generally in the setting of severe inadequate insulin action.

A disulfide bond is the single covalent bond between the two adjacent sulfur chemical atoms in a disulfide, conventionally written $\mathrm{R}-\mathrm{S}-\mathrm{S}-{\mathrm{R}}^{\prime }$. Here $R$ and $R^{\prime }$ stand for the attached organic groups; they may belong to the same molecule or to initially separate molecules. A disulfide bond is a chemical bridge, rather than a hydrogen bond or a mere contact between nearby groups. Two thiols, $\mathrm{R}-\mathrm{SH}$ and ${\mathrm{R}}^{\prime }-\mathrm{SH}$, can supply its two sulfur endpoints. ^[ref]

The stoichiometry of forming a disulfide bond is especially revealing. Written as an oxidation half-reaction, it isThe reverse reduction half-reaction consumes two electrons and two hydrogen ions to restore two thiols. Both sides contain two sulfur chemical atoms; the two hydrogen chemical atoms have moved into the two hydrogen ions, and the net electric charge remains zero because $+2-2=0$. Thus one disulfide bond corresponds to two thiol groups and two transferred electrons. These half-reactions describe redox bookkeeping, not a complete standalone chemical reaction: an accompanying reactant must accept or supply the electrons, and pH affects the actual protonation of the groups. Mercaptoethanol can promote reduction through exchange of disulfide bonds, but adequate excess and appropriate conditions are needed; adding it does not by itself prove complete reduction. ^[ref]

In a protein disulfide bond, the endpoints are normally the amino acid side chains of two cysteine amino acid residues. An intrachain protein disulfide bond closes an intramolecular bridge within one polypeptide chain; an interchain protein disulfide bond connects different polypeptide chains, and can arise by intermolecular crosslinking of initially separate molecules. Forming or reducing these bridges changes covalent bond connectivity and can change protein structure, while preserving the order of amino acid residues and the peptide bonds in the protein backbone. A complete chemical account of protein primary structure includes crosslinks as well as sequence, so preservation of sequence does not imply preservation of every covalent bond. Mature insulin has two interchain protein disulfide bonds and one intrachain protein disulfide bond. ^[ref]

A bridge is useful because it constrains which parts of a polypeptide chain can move apart without breaking a covalent bond. Its placement therefore matters as well as its presence. The ribonuclease A refolding experiment provides the existing experimental example: breaking and reforming four protein disulfide bonds can accompany loss and recovery of function. Counting four bridges alone cannot tell whether their endpoints have the native pairing. This is an attractive connection between simple chemical counting and the richer problem of protein folding.

How can an experiment reveal an initially hidden disulfide bond? Ellman's reagent, also called DTNB, measures free thiols by producing a yellow absorbing species. Its reactive disulfide bond undergoes exchange with the conjugate base $\mathrm{R}-{\mathrm{S}}^{-}$ of a thiol, producing a mixed disulfide attached to $R$ and one released 2-nitro-5-thiobenzoate species, abbreviated TNB. At the assay pH, the strongly colored form is the dianion $\mathrm{TN}{\mathrm{B}}^{2-}$: one negative charge is on sulfur and the other is on the carboxylic acid-derived $\mathrm{CO}{\mathrm{O}}^{-}$ group. With excess DTNB and complete reaction, one released TNB reports one reacted thiol. George L. Ellman's 1959 paper introduced the tissue assay; it was subsequently reexamined quantitatively. ^{[ref] [ref]}

The modern apparatus can be simple: tubes, pipettes, a buffer solution, cysteine standards, DTNB, and an instrument that measures absorbance through a cuvette at wavelength $412\mathrm{nm}$. The Pierce protocol uses $50\mu \mathrm{L}$ of a $4\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ DTNB stock, $2.50\mathrm{mL}$ of buffer solution, and $250\mu \mathrm{L}$ of sample. Its buffer solution is $0.1\mathrm{mol}{\mathrm{L}}^{-1}$ sodium phosphate at pH 8.0 with a metal-binding additive. After 15 minutes at room temperature, measure absorbance against a buffer solution plus DTNB blank; run known cysteine concentrations in parallel. The observable is increased yellow color and increased blank-corrected absorbance as more accessible thiols react, rather than direct imaging of disulfide bonds. These are published protocol conditions, not measurements performed for this article. ^[ref]

For a before/after test, split a purified protein sample into matched aliquots. Measure accessible free thiols in one aliquot; subject the other to complete reduction of its disulfide bonds, remove the reducing reagent, then measure the resulting thiols with fresh DTNB. Process the unreduced aliquot through a matching cleanup. Normalize to recovered protein and known dilution, since cleanup can change both. To estimate all reducible protein disulfide bonds, expose buried groups using matching protein denaturation conditions in both aliquots and calibrate in that same chemical solution; a native-accessibility measurement answers a different question. A larger corrected reading after reduction supports conversion of previously unreactive groups into detectable thiols. Attribution to disulfide bonds requires excluding other reducible sulfur modifications. This is a proposed comparison based on the detection principles, not a reconstruction of Ellman's original tissue measurements. ^[ref]

Under the Beer-Lambert law, the blank-corrected absorbance is $A=\epsilon lc$, where $l$ is the cuvette path length, $c$ is the released TNB concentration, and $\epsilon$ is its molar absorption coefficient. Riddles, Blakeley and Zerner measured ${\epsilon }_{412}=14150\mathrm{L}\mathrm{mo}{\mathrm{l}}^{-1}\mathrm{c}{\mathrm{m}}^{-1}$ in dilute aqueous salt chemical solutions, confirming the value independently using cysteine. It must not be applied indiscriminately to other solvents or protein denaturation mixtures. ^[ref] For aliquots compared on the same final volume and protein concentration basis, the ideal estimate isThe factor of two follows from the reduction stoichiometry; ${\bar{n}}_{\mathrm{S}-\mathrm{S}}$ is the number of disulfide bonds per protein molecule, or an average for a mixed population. If the aliquots have different dilutions or recoveries, convert each reading to a common sample basis before subtracting.

As a hypothetical calculation, choose $c_{\mathrm{protein}}=10\mu \mathrm{mol}{\mathrm{L}}^{-1}$ in each final cuvette, two free thiols and two disulfide bonds per protein molecule, and $l=1\mathrm{cm}$. Before reduction, $c_{\mathrm{SH}}=20\mu \mathrm{mol}{\mathrm{L}}^{-1}$ gives $A=0.283$; complete reduction adds four thiols per protein molecule, so $c_{\mathrm{SH}}=60\mu \mathrm{mol}{\mathrm{L}}^{-1}$ gives $A=0.849$. The difference $0.566$ gives $c_{\mathrm{S}-\mathrm{S}}=20\mu \mathrm{mol}{\mathrm{L}}^{-1}$ and ${\bar{n}}_{\mathrm{S}-\mathrm{S}}=2$. The published tube volumes imply a dilution factor $2.80/0.250=11.2$; reversing that dilution multiplies both thiol and protein concentrations by 11.2 and leaves the bridge count per protein molecule unchanged.

Controls determine whether that arithmetic has chemical meaning. Use fresh cysteine standards and a processed blank without protein to detect color generated by residual reducing reagent. Even a reducing reagent containing no thiols can interfere: Han and Han showed that tris(2-carboxyethyl)phosphine, abbreviated TCEP, reduces DTNB to two TNB equivalents per TCEP. ^[ref] In the hypothetical model, $5\mu \mathrm{mol}{\mathrm{L}}^{-1}$ residual TCEP in only the reduced cuvette would add $A=0.1415$ and falsely add $0.5$ bridge per protein molecule. A stable endpoint and agreement after a further reduction treatment help check completion. A sample without DTNB checks its own color; cloudy samples can also attenuate light without producing TNB. Match pH, temperature, accessibility and calibration chemical solution, and minimize delay that permits reoxidation. If two already-free but buried thiols become accessible only in the reduced aliquot, they mimic one new disulfide bond per protein molecule. Finally, bulk absorbance supplies a count under these assumptions: it does not locate the cysteine endpoints, distinguish intrachain from interchain bridges, or establish the native pairing of a protein disulfide bond.

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

Glucose clamp technique: a method for quantifying insulin secretion and resistance. by R. A. DeFronzo and others separates two questions. In a hyperglycemic clamp, variable glucose infusion holds blood glucose above baseline while sampled insulin reports the response. The 1979 article's abstract reports an early release burst followed by a slower rise. In a euglycemic insulin clamp, infused insulin is held elevated and variable glucose infusion holds blood glucose at baseline. Frequent blood sampling, a glucose analyzer, and controlled infusion apparatus make the imposed concentration a maintained condition rather than an uncontrolled consequence. ^[ref][ref]

The maintained glucose level controls an important confounder: a change in blood glucose would itself change uptake and hormone release. At a steady state, conservation of mass gives uptake equal to infused supply plus endogenous production, after accounting for losses. Consequently, infusion alone estimates uptake only if endogenous production is negligible and the other balance assumptions hold. Labelled glucose measurements can estimate residual endogenous production; matching infused insulin across comparisons matters. Whole-body uptake cannot by itself identify the responding tissue, and plasma insulin reflects both release and removal. This interpretation uses the accessible 1979 abstract and the later authored methods chapter; the original article's full methods were not available for inspection.^[ref]

Glycine is an amino acid, represented by Gly or G for an incorporated amino acid residue. Its amino acid side chain is a hydrogen chemical atom. It was identified at one insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names, symbols and structures.

Glycogenesis builds glycogen; glycogenolysis breaks it down. Their opposing directions matter in the insulin and glucagon circuit.

Homeostasis is the maintenance of usable internal conditions despite disturbances. It concerns selected regulated physiological variables, rather than keeping every part of an organism unchanged: core body temperature may remain near its usual range while skin temperature, sweating and blood pressure change. Regulation makes a relatively dependable environment for biological cells out of a changing external world. ^[ref]

A useful causal description separates a physiological sensor, a physiological integrator and a physiological effector. The return from the physiological effector's action to the sensed regulated physiological variable closes a feedback control loop. In negative feedback, that return opposes the disturbance. The insulin and glucagon articles already trace the blood glucose example; synaptic integration explains how several inputs can jointly influence a neuron. These are implementations and ingredients, not a requirement that every regulatory loop use one anatomical control center. ^[ref]

Homeostasis is useful precisely because internal activity can change: a nearly steady temperature can conceal a large increase in heat transfer. Conversely, observing a flat trace alone does not identify a regulatory mechanism. The environment might simply be constant, or the measuring instrument too insensitive; a perturbation and an independent response readout provide stronger evidence. The skin-temperature perturbation experiment below makes that distinction tangible.

The historical motivation was the puzzle of stability in changing living material. In his 1932 The Wisdom of the Body, Walter Bradford Cannon emphasized that an organism exchanges material with its surroundings and continually replaces its own structure, yet maintains relatively steady internal conditions. This authored excerpt presents homeostasis as active compensation for external and internal disturbances, rather than a static body. ^[ref]

Insulin is a protein hormone. Its mature form has two polypeptide chains; identifying their sequences and protein disulfide bonds provided the motivating example in Sanger's insulin sequencing experiment. See Cooper: insulin as a two-chain hormone, figure 2.16.

A meal illustrates the insulin side of blood glucose homeostasis: rising glucose stimulates beta cells in the pancreatic islets, and released insulin favors uptake and storage of fuel. Alpha cells produce glucagon, while delta cells produce somatostatin, which inhibits release of both insulin and glucagon. The pancreas therefore contains interacting sensor and secretory biological cells, rather than one undifferentiated source of hormones. ^[ref]

Insulin and glucagon are peptide hormones, built from amino acid residues joined by peptide bonds; glucose is a small carbohydrate molecule. A hormone changes signal transduction, not the identity of the fuel it regulates. Human mature insulin has 51 amino acid residues in two polypeptide chains. Beta cells process proinsulin to insulin and C-peptide, storing the products in secretory granules for exocytosis. Increased glucose metabolism raises the ATP-to-ADP ratio, tending to close ATP-sensitive potassium channels; depolarization and entry of calcium ions then trigger exocytosis. This is an important triggering pathway, with additional amplification and modulatory inputs.^[ref]

Binding to the insulin receptor, a receptor tyrosine kinase, starts phosphorylation of the receptor and insulin receptor substrates. Recruitment of phosphoinositide 3-kinase and activation of Akt transmit a major metabolic branch. In skeletal muscle and adipose tissue, that branch helps move GLUT4 to the cell membrane, increasing glucose uptake by facilitated diffusion. GLUT4 is a membrane transport protein, not an insulin receptor. Insulin also favors glycogenesis in skeletal muscle and the liver, and inhibits lipolysis in adipose tissue. In the liver, suppression of glucose output involves enzyme regulation, gene expression, and indirect changes in substrate supply. Its relative direct and indirect contributions are more complex than a single Akt arrow. ^[ref]

Insulin is not a universal permission slip for glucose entry: red blood cells and much of the nervous system use uptake mechanisms that are not acutely dependent on insulin. Nor does the liver use the same GLUT4 switch as skeletal muscle. This is why reduced insulin action can change blood glucose dramatically without stopping all glucose uptake. ^[ref]

Diabetes can disrupt production, response, and counterregulation. Type 1 diabetes usually involves destruction of beta cells and severe loss of endogenous insulin; type 2 diabetes combines insulin resistance with insufficient beta cell compensation. High circulating insulin can therefore coexist with impaired insulin action. Inappropriate glucagon release can add to excessive liver glucose output, and the response to low blood glucose can also be impaired: "more glucagon" is not a complete description of diabetes. These distinctions explain mechanisms, rather than prescribe treatment. ^{[ref] [ref]}

The mature insulin receptor already contains two extracellular $\alpha$ chains and two membrane-spanning $\beta$ chains, joined through protein disulfide bonds, before insulin binds. Insulin induces rearrangement of this $(\alpha \beta {)}_2$ assembly. Partner-mediated phosphorylation of the inhibitory activation loop permits increased protein kinase activity. Ligand-induced creation of a previously absent dimer is therefore an unsuitable universal explanation.^[ref]

An insulin receptor substrate is a docking protein phosphorylated by the activated insulin receptor. Its phosphotyrosine residues recruit downstream signaling proteins, including SH2 domain-containing components of phosphoinositide 3-kinase. This connects reception to the pathway described under insulin, rather than making the insulin receptor substrate another extracellular ligand.^[ref]

A reduced biological response to insulin; it is a property of response, not simply a low insulin concentration. The glucose clamp technique helps separate these quantities.

Intraislet glucagon signaling is critical for maintaining glucose homeostasis by Lu Zhu and others tested whether local glucagon supports insulin release. For human pancreatic islets, a computer-controlled flow system delivered a buffer solution at $1\mathrm{ml}/\min$ through a chamber holding 500 pancreatic islets on a nylon filter at $37{}^{\circ }\mathrm{C}$. A fraction collector sampled the outgoing fluid. With an amino acid mixture present, the experiment changed glucose from $3$ to $16.7\mathrm{mM}$ and compared GLP-1 receptor blockade with fluid lacking the blocker. The readout was released insulin and glucagon: blockade reduced glucose-stimulated insulin release without significantly changing glucagon release. ^[ref]

Complementary mouse experiments suppressed alpha cell activity using an engineered G protein-coupled receptor. ELISA assays of minute-by-minute effluent samples measured insulin and glucagon concentrations, providing the hormone release readout. Drug-treated control pancreatic islets lacking that engineered receptor checked for drug effects; adding glucagon restored insulin release in the suppressed preparation. Together, blockade and rescue support local signal transduction from alpha cells to beta cells. Isolated pancreatic islets omit intact circulation and nervous input; the human preparation came from five donors, and blocker specificity and donor variation limit generalization. A chamber response does not directly measure whole-body blood glucose control. ^[ref]

A metabotropic receptor couples ligand recognition to intracellular signal transduction, which can regulate a separate ion channel, alter enzyme activity or change gene expression. In the usual neurotransmitter context, metabotropic receptors are G protein-coupled receptors: receptor activation is relayed by a G protein. There need not be a change in membrane potential at all. ^[ref]

Two routes should be distinguished. An activated G protein can regulate an ion channel locally at the cell membrane, without an obligatory diffusible second messenger. Alternatively, it can regulate an enzyme that changes the availability of a second messenger, such as cAMP or inositol trisphosphate. Downstream proteins then change channel opening, phosphorylation or other cellular activities. The receptor, G protein, second messenger and final target are distinct components; an activated G protein is a relay protein, rather than itself a small-molecule second messenger.^[ref]

Do not turn this useful chemical synapse classification into the claim that every receptor is a GPCR, or that every indirect response must pass through a G protein. For example, the insulin receptor is an enzyme-linked cell-surface receptor whose intracellular catalytic activity initiates protein phosphorylation. Intracellular receptors supply another category. “Metabotropic” commonly names the GPCR branch in neuroscience; the broader idea of biochemical coupling does not make all non-channel receptors structurally identical. ^[ref]

Separating recognition from execution allows signal amplification and branching. A persistently activated receptor can activate several relay proteins; a regulated enzyme can produce many second messenger molecules. As an explicitly invented count example, suppose one activated receptor activates four relay proteins during one interval, and each relay activates a distinct enzyme that produces fifteen second messenger molecules during the next interval. With sufficient substrates and no loss, this gives $4\times 15=60$ molecules. Those counts do not specify a physiological gain or response duration. A directly gated ion channel also passes many ions while open, so amplification is not an exclusive property of metabotropic receptors: always name the input and output being compared. ^[ref]

A particularly instructive electrophysiology experiment separated a chemical trigger from the ion channel carrying its eventual electric current. In 1987, Hirono, Ito and Sugiyama injected messenger RNA from rat brain into frog egg cells, then tested acquired responses to neurotensin and muscarinic acetylcholine stimulation. Under voltage clamp at $-60\mathrm{mV}$, neurotensin elicited transient, oscillatory inward electric currents after a delay of several tens of seconds. This delay refers to that response and preparation. Reversal potential measurements implicated increased permeability to chloride anions, rather than a pore specific to the applied ligand. Both neurotensin and acetylcholine responses were inhibited by pertussis toxin, which interferes with susceptible G proteins, and by intracellular EGTA, which binds free calcium. Injecting inositol trisphosphate mimicked the responses; a large prior dose of inositol trisphosphate reduced subsequent responses to either extracellular signal. These interventions implicate a shared intracellular relay and calcium-dependent channel opening.^[ref]

The informative comparison with the nicotinic acetylcholine receptor experiment is mechanistic: an extracellular ligand can produce an inward electric current either by directly gating the pore or by mobilizing an intracellular second messenger and stored calcium that activate another pore. Intracellular inositol trisphosphate bypasses reception, whereas EGTA tests the need for free calcium. However, neither inhibition nor mimicry alone identifies every molecular connection: a perturbation can affect several targets, and an injected mediator can activate a pathway without proving that it is the only natural route. The egg cell's endogenous machinery and the mixed messenger RNA preparation also limit extrapolation to an intact neuron. The experiment establishes functional coupling in its preparation, rather than the exact molecular composition or timing of every metabotropic receptor.

Even G protein-dependent channel regulation need not involve a lengthy second messenger cascade. Pfaffinger and colleagues reported in 1985 that acetylcholine-evoked potassium channel activation in embryonic chick atrial cells required intracellular GTP, a guanine-containing nucleotide, and was abolished by pertussis-toxin pretreatment. Changes in cyclic nucleotides, including cAMP, did not account for the channel response. The report discusses intrinsic activation delays of roughly $30$–$100\mathrm{ms}$, illustrating relatively rapid metabotropic receptor action. These observations support a G protein coupling step without cyclic-nucleotide second messengers; they do not by themselves exclude every possible intermediary or prove the specific subunit-channel interaction.^[ref]

A small timing model makes the extra steps visible without inventing an experimental trace. Let $u(t)$ jump from zero to one at $t=0$ and remain on. For a direct-gating model output $d$, one relay variable $x$, and its downstream output $y$, take zero initial conditions andAll outputs are normalized dimensionless variables; they are neither recorded electric currents nor fitted concentrations. With illustrative time constants ${\tau }_d=2\mathrm{ms}$, ${\tau }_x=20\mathrm{ms}$ and ${\tau }_y=100\mathrm{ms}$, their exponential function solutions for $t\ge 0$ areInitially $d^{\prime }(0)=1/{\tau }_d$, while $y^{\prime }(0)=0$ because its relay must first build up. Both outputs eventually approach one. Equal normalized final values do not imply equal biological amplitudes or absence of signal amplification; normalization deliberately removes that question.

The model's useful feature is the delayed buildup created by sequential relaxation, not its arbitrary numbers. Actual kinetics also depend on ligand delivery, relay deactivation, neurotransmitter clearance and the final target. A local G protein route can act promptly, while an ionotropic receptor can remain active during continued exposure or feed a longer-lasting intracellular response. The beauty of metabotropic receptor coupling is its flexibility: the same recognition event can adjust electrical responsiveness and other cellular tasks through different targets. To classify an observed response, combine timing with molecular identity and controlled perturbations.

Location determines access to substrates, cofactors and transport routes; identical catalytic potential can therefore serve different physiological functions in different compartments. In carbohydrate metabolism, the plasma membrane, mitochondrion and endoplasmic reticulum are selective barriers, not merely containers. A soluble enzyme cannot use a metabolite efficiently if that metabolite cannot reach its compartment, while transporter abundance matters chiefly when the transporter is in the appropriate membrane.

Most glycolysis occurs in the cytosol, whereas pyruvate dehydrogenase complex and much oxidative metabolism occur in the mitochondrial matrix. Pyruvate entry therefore links cytosolic glucose breakdown to mitochondrial oxidation. Cytosolic NADH does not freely cross the inner mitochondrial membrane: the malate-aspartate shuttle and glycerol phosphate shuttle transfer reducing equivalents through different routes. Their operation affects the energetic outcome of glucose use. In gluconeogenesis, mitochondrial pyruvate carboxylase produces oxaloacetate, but oxaloacetate itself does not freely cross that membrane. Conversion into transportable intermediates, or formation of phosphoenolpyruvate in the appropriate compartment, allows carbon to reach cytosolic steps. Enzyme localization thus imposes an obligatory transport and redox problem, not just an extra reaction label.

At the final step of hepatic glucose production, the catalytic site of glucose-6-phosphatase faces the endoplasmic-reticulum lumen. Glucose-6-phosphate must reach it through the associated transport system. Hydrolysis makes free glucose available for export, whereas the phosphate ester is largely retained by membranes. Muscle can mobilize cytosolic glycogen to glucose-6-phosphate for its own glycolysis, but lacks the hepatic glucose-6-phosphatase system needed for substantial release of that carbon as free blood glucose. Tissue function therefore depends on both enzyme expression and the membrane machinery surrounding the enzyme.

Transporter traffic changes function without waiting for new protein synthesis. In resting muscle and adipose cells, much GLUT4 resides in intracellular vesicles. Insulin signalling promotes its delivery to the cell surface and increases glucose uptake; internalization subsequently reduces surface transport capacity. Classical membrane-fractionation and transport-site measurements supported redistribution from an intracellular pool to the plasma membrane.^[ref] Fractionation requires compartment markers, and surface labelling or microscopy provides an independent check: altered fraction recovery alone could otherwise mimic redistribution. Total cellular GLUT4 is not an adequate proxy for surface uptake capacity.

Polarity provides another example. In intestinal epithelial cells, apical SGLT1 uses the sodium electrochemical gradient to take up glucose, whereas basolateral GLUT2 enables exit towards the circulation. Basolateral sodium-potassium ATPase maintains the sodium gradient. Misplacing a transporter can disrupt vectorial absorption despite normal intrinsic transport activity. Glycogen-associated regulatory enzymes similarly gain access to a localized substrate pool. These examples show why localization should be tested with activity and transport measurements as well as images. Compartmentation creates direction, regulation and tissue specialization, while requiring transporters that connect the separated reactions.

Diabetes is a disorder of glucose regulation with persistent hyperglycaemia; the glycosuria is a consequence, not a sufficient explanation of its cause. In 1865 the relation between hepatic glycogen, circulating glucose and urinary sugar was actively disputed. A contemporary account could reasonably discuss failure to assimilate food and excessive delivery of sugar from the liver; it could not possess the later demonstration of insulin deficiency. An 1863 discussion of diabetes documents competing interpretations of the hepatic experiments, rather than an agreed single lesion.^[ref]

In the modern account, type 1 diabetes results from destruction of pancreatic beta cells and severe deficiency of insulin. Type 2 diabetes combines insulin resistance with inadequate compensatory insulin secretion. Disease of the pancreas can also cause diabetes. Reduced restraint of hepatic glucose production and impaired peripheral disposal of glucose contribute to hyperglycaemia. These mechanisms distinguish types that were not separated in the question's terminology.^[ref]

When the filtered glucose load exceeds renal reabsorptive capacity, glycosuria causes an osmotic diuresis: loss of water and electrolytes produces polyuria, dehydration and polydipsia. Inadequate use of fuels and increased breakdown of stored fat and protein explain wasting despite appetite. Severe insulin deficiency promotes ketogenesis and can cause diabetic ketoacidosis; it is not correct to make this the inevitable state of everyone with diabetes. Conversely, renal glycosuria can occur without the systemic metabolic disorder, so a urinary sugar test alone does not settle the diagnosis.Symptoms and signs; complications: glycosuria and osmotic diuresis^[ref]

The associated diseases should be separated into predispositions, complications and coincident illnesses. Pulmonary wasting called “phthisis” was prominent in period accounts, but the historical label does not establish that every reported lung cavity was tuberculous.^[ref] Modern diabetes increases susceptibility to active tuberculosis; it does not convert sugar into tubercle. Diabetes also increases susceptibility to some other infections and can accompany recurrent skin infection, poor wound healing and gangrene.^[ref] Long-standing hyperglycaemia is associated with retinopathy, nephropathy and peripheral neuropathy; accelerated atherosclerosis contributes to coronary artery disease, stroke and limb ischemia. Obesity is commonly associated with type 2 diabetes, although severe untreated disease may cause loss of body mass. None of these associations licenses a claim that every diabetic patient has the same anatomical lesions.^[ref]

For an 1865 investigation, repeated urine testing could demonstrate reducing sugar and its variation with diet; simultaneous study of the blood and liver was needed to investigate the source. The distinction between glucose already present during life and glucose formed in an unfixed liver after death is crucial experimental design: post-mortem chemical change must not be mistaken for the living organ's output. Modern diagnosis measures blood glucose and longer-term glycaemic exposure rather than inferring the entire disorder from the taste or appearance of urine.^[ref]

Phenylalanine is an amino acid, represented by Phe or F for an incorporated amino acid residue. It was identified at the other insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names and symbols.

A single polypeptide precursor whose processing yields mature insulin and C-peptide; it is not the two-chain mature hormone. The biosynthetic distinction is described under insulin.

The protein primary structure specifies the ordered amino acid residues of each polypeptide chain, joined through peptide bonds. A chain is conventionally written from its N-terminus to its C-terminus. In the broader chemical sense, a complete protein primary structure also specifies covalent bond crosslinks between chain positions, including protein disulfide bonds; a bare sequence string leaves that information unstated. This describes chemical connectivity rather than the spatial arrangement of protein tertiary structure or protein quaternary structure. See IUPAC Gold Book: primary structure, sequence and chain crosslinking and IUPAC-IUB, 3AA-16: writing residue sequences from the amino end. Some conventions reserve protein primary structure for sequence alone and call the complete chemical connectivity the covalent structure; the distinction should be stated when comparing descriptions. See IUPAC-IUB polypeptide-conformation recommendations, section 6.1: the narrower sequence-only convention.

In this toy example M denotes methionine, A alanine and G glycine. Both polypeptide chains have six amino acid residues, five peptide bonds, an M at the N-terminus and a G at the C-terminus. Their amino acid composition is identical, yet position 2 is A in MAGAMG and M in MMAAGG. There are $6!/(2!2!2!)=90$ distinct orders with these counts, a multinomial coefficient. Even fixing those two end residues leaves $4!/(1!2!1!)=12$ orders. The counts constrain the answer without determining it.

For multiple polypeptide chains, record each sequence separately and specify any protein disulfide bonds between cysteine positions. Mature insulin, for example, has an A chain of 21 amino acid residues and a B chain of 30 amino acid residues. Their combined 51 residues give $(21-1)+(30-1)=49$ peptide bonds, rather than the 50 of one unbroken 51-residue chain. See Cooper, The Cell: insulin's two chains and cysteine crosslinks, figure 2.16. A protein disulfide bond joins side groups; it does not concatenate the C-terminus of one chain with the N-terminus of another. The three insulin protein disulfide bonds connect A6 to A11 within the A chain, and A7 to B7 and A20 to B19 between chains. Positions are numbered from each chain's N-terminus. See Replacement of the interchain disulfide bridge-forming amino acids A7 and B7 by glutamate impairs the structure and activity of insulin: native disulfide positions.

Why keep this information? Protein primary structure lets us distinguish changes of chemical identity from changes of shape, and compare corresponding positions between proteins. Protein folding can bring distant amino acid residues together at a protein binding site while preserving their sequence. The attractive idea is that a readable linear record can constrain a complicated three-dimensional object; it is not, by itself, a guarantee of a unique fold in every environment. See protein folding and the ribonuclease A refolding experiment. Merely bending an intact chain preserves its protein primary structure; hydrolysis of a peptide bond, or changing which positions a protein disulfide bond connects, changes its chemical connectivity.

A regulated physiological variable is a specified internal quantity whose departures elicit actions tending to restore an appropriate range. Examples include core body temperature, blood glucose concentration, blood pressure, and the pH and osmolality of extracellular fluid. Specify the compartment and readout: skin temperature and core body temperature are different quantities, and an insulin concentration is a regulatory message rather than the blood glucose it helps control.